Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder
Sage Therapeutics announced positive top-line results from the Phase 2
Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression
Sage therapeutics announced positive top-line results from two Phase 3 clinical trials with its proprietary i.v. formulation of brexanolone
Can laughing gas help deter suicide?
Researchers studying use of nitrous oxide for patients hospitalized for suicide risk
Caring for mom & baby
Children’s outcomes improve when perinatal mental health issues are addressed.
Hard-to-treat depression in seniors focus of $13.5 million study
Goal is to identify strategies most likely to work for specific patients
Nagele honored by Society of Biological Psychiatry
Award recognizes standout research published in the journal Biological Psychiatry
Exploring a new way to diagnose mental illness
New grant from the National Institute of Mental Health will fund study of structural and functional connectivity of patients with psychiatric disorders.
Laughing gas studied as depression treatment
Results from pilot study indicate improvement after receiving nitrous oxide in two-thirds of patients with treatment-resistant depression.
New clue to autism found inside brain cells
Study indicates activity of mGlu5 receptors plays role in memory, social and cognitive problems.
New target explored for psychiatric drug development
Naturally occurring molecule could offer new treatments for schizophrenia and other mental illnesses.
